A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes

Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (gBRCA1/2)-mutant advanced breast cancer, but its activity beyond gBRCA1/2 is poorly understood. We conducted Talazoparib Beyond BRCA (NCT02401347), an open-label phase II trial, to evaluate talazoparib in patients with pretreated...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruber, Joshua J., Afghahi, Anosheh, Timms, Kirsten, DeWees, Alyssa, Gross, Wyatt, Aushev, Vasily N., Wu, Hsin-Ta, Balcioglu, Mustafa, Sethi, Himanshu, Scott, Danika, Foran, Jessica, McMillan, Alex, Ford, James M., Telli, Melinda L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586861/
https://www.ncbi.nlm.nih.gov/pubmed/36253484
http://dx.doi.org/10.1038/s43018-022-00439-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586861/
https://www.ncbi.nlm.nih.gov/pubmed/36253484
http://dx.doi.org/10.1038/s43018-022-00439-1

Ejemplares similares